FDA expects the continuing medical education program that is the heart of the Risk Evaluation and Mitigation Strategies for long-acting/extended-release opioids to begin by March 1, 2013.
“There are approximately 320,000 prescribers of ER/LA opioid analgesics in the United States, and FDA expects companies to train 25%...